It was our pleasure to meet Prof. Carolyn Lam from the National Heart Centre, Singapore, and discuss this significant study to learn how it is moving forward.
ADOPT (Asian Diabetes Outcomes Prevention Trial) is a prospective, multinational randomized open-label study conducted in Asia Pacific (Taiwan, China, India, Malaysia, and Singapore) aiming to include 2,400 adults with type 2 diabetes without known cardiovascular disease.
This trial is investigating whether intensive preventive therapy (high dose renin-angiotensin-aldosterone system inhibitors, beta-blockade, sodium-glucose co-transporter 2 inhibitors) among biomarker (NT-proBNP) identified high-risk type 2 diabetes patients without pre-existing cardiovascular disease, may be associated with reduced cardiovascular events compared to standard of care.